Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

n the recently completed Phase Ib clinical trial of ANA598 in HCV patients in a late-breaker poster entitled, "Antiviral Activity of ANA598, a Potent Non-Nucleoside Polymerase Inhibitor, In Chronic Hepatitis C Patients," at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). In the Phase Ib study, ANA598 treatment resulted in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding 2 log10 (>99%) at all dose levels. At 200 mg bid, the median viral load reduction was 2.4 log10 (range of 0.4 to 3.4); at 400 mg bid, 2.3 log10 (range of 1.6 to 3.5); and at 800 mg bid, 2.9 log10 (range of 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 at 200, 400 and 800 mg bid, respectively. In 10 of the 12 genotype 1a patients who received ANA598, viral load was still declining at the end of the three days of treatment. Genotype 1b patients demonstrated median reductions of 2.6 log10, 2.5 log10 and 3.2 log10, at 200, 400 and 800 mg bid, respectively. No patient showed evidence of viral rebound while on ANA598. ANA598 was well-tolerated in this short term study and there were no serious adverse events.

  • 14-day Healthy Volunteer Study. Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received a single dose on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, al
    '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual ... monetization of intellectual property, announced today that the ... Uniden in the U.S. District Court for the ... has been rescheduled for November 10, 2014.  This ... The Court Order setting the Markman date was ...
(Date:10/1/2014)... Irvine, CA (PRWEB) September 30, 2014 ... for user-friendly, cost-effective tools to address sales, training ... PMG has developed innovative mobile applications to ... studies, outlining the agency’s latest customized mobile app ... http://www.studiopmg.com/work . , In partnership with Toyota, ...
(Date:10/1/2014)... Ill. (PRWEB) October 01, 2014 The ... $9,956,011 to Southern Illinois University Edwardsville as part of ... (TAACCCT) initiative. The funding is co-administered by the Department ... Joe Biden, Secretary of Labor Thomas E. Perez and ... $450 million in job-driven training grants to nearly 270 ...
(Date:9/30/2014)... This news release is available in German . ... at the Technische Universitt Mnchen (TUM) have demonstrated a ... Their experiments show that future computer chips could be ... transistors. As the main enabling technology of the semiconductor ... fundamental limits, the TUM researchers and collaborators at the ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3
... ... ... , , , ... ...
... ... web to cost effectively boost the pool of eligible patients for screening for any ... upload recruitment material approved by their Institutional Review Board (IRB), on their own specific ... ...
... ... ... ... ...
Cached Biology Technology:Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM) 2Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM) 3Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM) 4RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™ 2RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™ 3China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 2China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 3China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 4China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 5China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 6China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility 7
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... wrong with your muscles because of age, disease or injury, ... That,s where a new research report published in the October ... comes in. In the report, a team of scientists produce ... scientists "see" which genes are active in an organ at ... and that men have approximately 400 more active genes in ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... National Institute of Standards and Technology (NIST) have ... clumps of proteins in protein-based pharmaceuticals. This first ... can be assured that their instruments are faithfully ... concern because of its impact on quality control ...
... laundry products and air fresheners found the products emitted ... off at least one chemical regulated as toxic or ... was listed on the product labels. , "I first ... me that the air fresheners in public restrooms and ...
... the first issue of , Energy & Environmental Science ... Free for all to read online, this inaugural ... hydrogen storage, thermochemical biofuel production, sustainable energy, and much ... of the highest quality, knowing that they can rely ...
Cached Biology News:NIST trumps the clumps: Making biologic drugs safer 2Toxic chemicals found in common scented laundry products, air fresheners 2Toxic chemicals found in common scented laundry products, air fresheners 3